Keywords: ADA; anti-drug antibody; nADA; neutralizing anti-drug antibody; PASI; Psoriasis Area and Severity Index; PK; pharmacokinetics; Q2W; every 2 weeks; Q4W; every 4 weeks; TE-ADA; treatment-emergent anti-drug antibody;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: AE; adverse event; ACR; American College of Rheumatology; Apo; apolipoprotein; BID; twice daily; BP; blood pressure; CHF; congestive heart failure; CRP; C-reactive protein; csDMARD; conventional synthetic disease-modifying antirheumatic drug; CV; cardiova
Keywords: aBMD; areal bone mineral density; app; apparent; BMD; bone mineral density; BV/TV; bone volume fraction; Ct.Th; cortical thickness; DXA; dual-energy X-ray absorptiometry; FE; finite element; HR-QCT; high-resolution quantitative computed tomography; Q2W; o
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial
Keywords: ACR; American College of Rheumatology; CRP; C-reactive protein; CTA; computed tomographic angiography; ESR; erythrocyte sedimentation rate; GCA; giant cell arteritis; HbA1C; hemoglobin A1C; MRA; magnetic resonance angiography; PET/CT; positron emission to
The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Keywords: ApoB/ApoA-I; Apolipoprotein B/Apolipoprotein A-I; ALT; Alanine aminotransferase; AST; Aspartate aminotransferase; CI; Confidence interval; CVD; Cardiovascular disease; CHD; Coronary heart disease; AMG 145; Evolocumab; Q2W; Every 2Â weeks; Q4W; Every 4Â we
PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
Keywords: PCSK9 inhibitors; Statins; Lipid lowering therapies; LDL-C; Low-density lipoprotein cholesterol; LDL-R; Low-density lipoprotein receptor; PCSK9; Proprotein Convertase Subtilisin/Kexin type 9; ACS; Acute coronary syndrome; FDA; Food and Drug Administration
Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE
Keywords: DTR; dosing table revision; ICS; inhaled corticosteroids; KDapp; apparent equilibrium binding constant; PK-PD; pharmacokinetic and pharmacodynamic; q2w; every 2Â weeks; q4w; every 4Â weeks; sc; subcutaneous; Allergic asthma; Anti-immunoglobulin E; Dosin
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials
Keywords: dyslipidemia; evolocumab; lipoprotein(a); PCSK9Â inhibition; CVD; cardiovascular disease; LDL; low-density lipoprotein; PCSK9; proprotein convertase subtilisin/kexin type 9; Q2W; every 2 weeks; Q4W; every 4 weeks; SC; subcutaneous; UC LDL-C; low-density l
Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes
Keywords: AUC; area under the curve; BMI; body mass index; FPG; fasting plasma glucose; GLP-1; glucagon-like peptide 1; HbA1c; glycosylated hemoglobin; ISR; insulin secretion rate; MTT; mixed-meal tolerance test; OGIS; oral-glucose insulin sensitivity; PPG; postpra